Podcast: Novartis’s $9.7bn Gamble; Higher Drug Prices Post-Brexit? Jefferies Highlights
Another Audio Instalment From The UK Team
Executive Summary
Join the London-based Eleanor Malone, Andrew McConaghie and Kevin Grogan as they review some of the most eyecatching stories in pharma and healthcare.
Scrip’s Andrew McConaghie and Kevin Grogan are back for a second instalment of their podcast covering some of the most eyecatching stories in pharma and healthcare.
For this episode, they’re joined by Eleanor Malone, Scrip’s Editor-in-Chief, Europe.
Covered in the podcast:
Novartis’ $9.7bn Gamble On The Medicines Company And Inclisiran
The Swiss big pharma company continues to broaden its drive into innovative drugs with the $10bn acquisition of The Medicines Company. Its chief asset is inclisiran, a RNAi lipid-lowering drug which should outperform Amgen Inc.’s Repatha and Sanofi and Regeneron Pharmaceuticals Inc.’s Praluent. But without cardiovascular outcomes data until potentally four years after its launch, can Novartis AG turn it into a blockbuster success?
Eleanor Malone looks at where the acquisition fits into Novartis' strategy, and the wider emergence of RNAi therapeutics.
The NHS, Brexit And US Pharma Prices
President Trump has this week been trying to play down allegations of secret US-UK talks about access to the UK market and the NHS for America's pharma industry. As the UK's election campaigning approaches its climax, Kevin Grogan looks into the substance of the claims made by Opposition leader, Labour's Jeremy Corbyn.
The Jefferies Healthcare Conference: Europe's Biopharma Showcase
The annual Jefferies Healthcare conference in London is Europe's biggest investor meeting, and continues to grow, with more and more biotech, pharma and medtech companies presenting each year. Andrew McConaghie reviews some of the highlights from this year's gathering, including the emergence of two heavyweight biotechs in Europe, Genmab AS and Galapagos NV.